Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
19 April 2022 |
Main ID: |
EUCTR2014-002475-29-NL |
Date of registration:
|
08/12/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Phase 2 clinical trial investigating the anti-virus effects, kinetics and safety of GS-5806 in adults with RSV (Respiratory Syncytial Virus) infection.
|
Scientific title:
|
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract |
Date of first enrolment:
|
10/02/2015 |
Target sample size:
|
60 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002475-29 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Canada
|
France
|
Germany
|
Israel
|
Korea, Republic of
|
Netherlands
|
Poland
|
Sweden
|
Taiwan
|
United Kingdom
|
United States
| | | | |
Contacts
|
Name:
|
Clinical Trials Mailbox
|
Address:
|
Flowers Building, Granta Park, Abington
CB21 6GT
Cambridge
United Kingdom |
Telephone:
|
+441223897284 |
Email:
|
clinical.trials@gilead.com |
Affiliation:
|
Gilead Sciences International Ltd. |
|
Name:
|
Clinical Trials Mailbox
|
Address:
|
Flowers Building, Granta Park, Abington
CB21 6GT
Cambridge
United Kingdom |
Telephone:
|
+441223897284 |
Email:
|
clinical.trials@gilead.com |
Affiliation:
|
Gilead Sciences International Ltd. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Males and females 18 to 75 years of age 2. Received an autologous or allogeneic HCT using any conditioning regimen 3. Evidence of new abnormalities on chest X-ray obtained < 48 hours prior to Screening, determined to be consistent with LRTI by the local radiologist, relative to the most recent chest X-ray. If chest X-ray is not available, a chest X-ray must be obtained for Screening. 4. Documented RSV in both the upper (eg, nasal swab, nasopharyngeal swab, nasal wash) and lower (eg, induced sputum, BAL, lung biopsy, but not spontaneous sputum) respiratory tract as determined by local testing (eg, PCR, DFA, RVP assay, or culture). All samples must have been collected = 6 days prior to Day 1 or as determined at Screening as per Section 6.1.1. 5. An informed consent document signed and dated by the subject or a legal guardian of the subject and investigator or his/her designee. In Sweden ICFs signed by legal guardian must also be signed by a close relative of the subject. 6. A negative urine or serum pregnancy test is required for female subjects (unless surgically sterile or greater than two years post-menopausal) 7. Male and female subjects of childbearing potential must agree to contraceptive requirements as described in Appendix 5 8. Willingness to complete necessary study procedures and have available a working telephone or email Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 45
Exclusion criteria: Related to concomitant or previous medication use: 1. Use of non-marketed (according to region) investigational agents within 30 days, OR use of any investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT 2. Use of a moderate or strong cytochrome P450 enzyme (CYP) inducer including but not limited to rifampin, St. John’s Wort, carbamazepine, and phenytoin, efavirenz, bosentan, etravirine, modafinil, and nafcillin, within 2 weeks prior to the first dose of IMP Related to medical history: 3. Pregnant, breastfeeding, or lactating females 4. Unable to tolerate nasal sampling required for this study, as determined by the investigator 5. Known history of HIV/AIDS with a CD4 count <200 cells/µL within the last month 6. History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities Related to medical conditions: 7. Requiring invasive mechanical ventilation at the time of randomization 8. Documented to be positive for other respiratory viruses (limited to influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus or coronavirus), from the lower respiratory tract sample as determined by local testing 9. Clinically significant bacteremia or fungemia within 7 days prior to Screening that has not been adequately treated, as determined by the investigator 10. Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated, as determined by the investigator 11. Excessive nausea/vomiting at screening, as determined by the investigator, or an inability to swallow pills that precludes oral administration of the IMP (for subjects without an NG tube in place) 12. Any condition which, in the opinion of the investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints Related to allergies: 13. Known hypersensitivity or allergy to the IMP, its metabolites, or formulation excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc) 14. History of hypersensitivity, anaphylactic reaction, Stevens-Johnson Syndrome, or toxic epidermal necrolysis response to sulfa drugs Related to laboratory results: 15. Creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault method) 16. Clinically significant AST/ALT, as determined by the investigator 17. Clinically significant TB, as determined by the investigator
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract. MedDRA version: 19.0
Level: LLT
Classification code 10039247
Term: RSV infection
System Organ Class: 100000004862
|
Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
Intervention(s)
|
Product Name: GS-5806 Product Code: GS-5806 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Presatovir CAS Number: 1353625-73-6 Current Sponsor code: GS-5806 Other descriptive name: GS-5806 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Main Objective: To evaluate the effect of presatovir on RSV viral load in autologous or allogeneic HCT recipients with an acute RSV LRTI
|
Secondary Objective: - To evaluate the effect of presatovir on being free of any supplemental oxygen, and rates of respiratory failure and all cause mortality - To evaluate the PK, safety, and tolerability of presatovir
|
Primary end point(s): Time-weighted average change in nasal RSV viral load (log10 copies/mL) from Baseline (Day 1) to Day 9 as measured by RT-qPCR
|
Timepoint(s) of evaluation of this end point: Day 1 to day 9 (daily measure)
|
Secondary Outcome(s)
|
Secondary end point(s): - Number of supplemental O2 free days through Day 28 - Proportion of subjects developing respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) through Day 28 - Proportion of all-cause mortality among subjects through Day 28
|
Timepoint(s) of evaluation of this end point: Day 28.
|
Secondary ID(s)
|
GS-US-218-1502
|
Source(s) of Monetary Support
|
Gilead Sciences, Inc.
|
Ethics review
|
Status: Approved
Approval date: 10/02/2015
Contact:
|
|